CGEM Stock Forecast: Cullinan Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.89
−1.98% on the day

The median 12-month analyst price target for Cullinan Therapeutics, Inc. is $35. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 67 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$577.1M
Ticker Nerd rank
67/ 100
Median analyst target
$35
Analysts covering
12
Revenue$0.0
Operating income−$57.3M
Net income−$53.7M
Free cash flow−$38.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.5%
1M
−40.1%
YTD
−14.1%
1Y
+1.9%
From 52W high
−61.3%
From 52W low
+1.9%
$9
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cullinan Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
67/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
81
Growth
74
Value
72
Momentum
69
Volatility
60
Quality
47
Revisions
44
Issuance
29

Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CGEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26CGEMHigh $44Median $35Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12
Buy
0
Hold
0
Sell
$27
Low
$35
Median
$44
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Nov 2026WedbushMaintainsOutperform$42 → $44
28 Oct 2026BTIGMaintainsBuy$40 → $41
19 Oct 2026BTIGReiteratesBuy$40
2 Oct 2026HC Wainwright & Co.ReiteratesBuy$35
25 Sept 2026BTIGReiteratesBuy$40
25 Sept 2026HC Wainwright & Co.MaintainsBuy$30 → $35
14 Sept 2026BTIGMaintainsBuy$39 → $40
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$30
13 Aug 2026WedbushMaintainsOutperform$39 → $42
29 July 2026BTIGMaintainsBuy$38 → $39
11 June 2026WedbushReiteratesOutperform$37
8 June 2026HC Wainwright & Co.ReiteratesBuy$30
19 May 2026BTIGReiteratesBuy—
8 May 2026WedbushMaintainsOutperform—
4 May 2026BTIGReiteratesBuy—
28 Apr 2026BTIGReiteratesBuy—
28 Apr 2026HC Wainwright & Co.MaintainsBuy—
11 Mar 2026WedbushMaintainsOutperform—
17 Feb 2026CitigroupInitiatesBuy—
2 Feb 2026GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CGEM.

Market Radar

This page is one stock. Monday covers all of them.

CGEM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CGEM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Cullinan Therapeutics, Inc. returned +1.9% against +6.9% for the S&P 500, dividends included.

CGEM vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26CGEMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.1×

Cheaper than 43% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−55.5%

Higher than 20% of US stocks

Return on assets
−33.9%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cullinan Therapeutics, Inc. has a market value of $577.1M and an enterprise value of $289.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$204.7M.

  • Diluted earnings per share, trailing twelve months: −$3.10.

  • Free cash flow in the twelve months to 30 June 2026: −$159.3M.

  • Shares outstanding: 64.3M.

  • Cullinan Therapeutics, Inc. employs 109 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

CGEM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGEMCullinan Therapeutics, Inc.$577.1M67
IMMXImmix Biopharma, Inc.$577.0M38
ENTXEntera Bio Ltd.$572.2M38
QUITAchieve Life Sciences, Inc.$572.1M44
ANNXAnnexon, Inc.$587.7M39
FDMT4D Molecular Therapeutics, Inc.$565.1M50
GERNGeron Corp.$557.7M71

Take a look at CGEM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cullinan Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CGEM

What is the CGEM stock price forecast for 2026-2027?

The median 12-month analyst price target for Cullinan Therapeutics, Inc. is $35, with estimates ranging from $27 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGEM stock a buy right now?

Of the 12 analysts covering Cullinan Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cullinan Therapeutics, Inc. 67 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGEM?

As at 21 Nov 2026, Cullinan Therapeutics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).

Will CGEM stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts is $35, and Ticker Nerd's factor model ranks Cullinan Therapeutics, Inc. 67 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGEM stock forecast for 2030?

No analyst covering Cullinan Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $44 over the next 12 months.

How has CGEM stock performed over the past year?

Cullinan Therapeutics, Inc. returned +1.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cullinan Therapeutics, Inc. do?

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates.

Company

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates. Its current programs address a range of serious conditions across oncology and immunology, such as non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, systemic lupus erythematosus, and rheumatoid arthritis. Cullinan Therapeutics works to advance differentiated drug candidates through early- and mid-stage clinical development, with a business model centered on discovering high-impact molecules and moving them toward proof of concept. Based in Cambridge, Massachusetts, Cullinan Therapeutics plays a role in the biotechnology market as a developer of precision therapies for diseases with significant unmet medical need.

CEO Mr. Nadim Ahmed M.S. · 109 employees · United States · https://cullinantherapeutics.com